WallStreetZenWallStreetZen

NASDAQ: GRFS
Grifols Sa Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

GRFS past earnings growth

How has GRFS's earnings growth performed historically?
Company
3.77%
Industry
-7.33%
Market
35.95%
GRFS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
GRFS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
GRFS's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

GRFS past revenue growth

How has GRFS's revenue growth performed historically?
Company
15.08%
Industry
-0.2%
Market
13.63%
GRFS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
GRFS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
GRFS's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

GRFS earnings and revenue history

Current Revenue
$6.5B
Current Earnings
$221.6M
Current Profit Margin
3.4%
GRFS's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

GRFS Return on Equity

Current Company
3.6%
Current Industry
46.8%
Current Market
188%
GRFS's Return on Equity (3.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when GRFS announces earnings.

GRFS Return on Assets

Current Company
1%
Current Industry
10.3%
GRFS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

GRFS Return on Capital Employed

Current Company
4.06%
Current Industry
16.5%
GRFS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

GRFS vs General Drug Manufacturer Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
GRFS$6.59B$1.31B$226.39M+4.47%-22.28%
OGN$6.17B$1.60B$754.00M-1.26%-34.36%
AMRN$346.27M-$44.75M-$38.30M+11.85%N/A
SCLX$46.46M-$46.30M-$53.79M+77.59%N/A
HZNP$3.64B$901.54M$438.00M+27.71%+34.31%
View Top General Drug Manufacturer Stocks

GRFS earnings dates

Next earnings date
Nov 2, 2023

Grifols Sa Earnings & Revenue FAQ

What was GRFS's earnings growth in the past year?

As of Q4 2023, Grifols Sa's earnings has grown 3.77% year over year. This is 11.1 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of -7.33%. Grifols Sa's earnings in the past year totalled $226.39 million.

If you're new to stock investing, here's how to buy Grifols Sa stock.

What is GRFS's earnings date?

Grifols Sa's earnings date is Invalid Date. Add GRFS to your watchlist to be reminded of GRFS's next earnings announcement.

What was GRFS's revenue growth in the past year?

As of Q4 2023, Grifols Sa's revenue has grown 15.08% year over year. This is 15.28 percentage points higher than the US Drug Manufacturers - General industry revenue growth rate of -0.2%. Grifols Sa's revenue in the past year totalled $6.59 billion.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.